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Abstract
Deregulated metabolism is a well-established hallmark of cancer. At the hub of various metabolic pathways deeply
integrated within mitochondrial functions, the α-ketoglutarate dehydrogenase complex represents a major
modulator of electron transport chain activity and tricarboxylic acid cycle (TCA) flux, and is a pivotal enzyme in
the metabolic reprogramming following a cancer cell’s change in bioenergetic requirements. By contributing to
the control of α-ketoglutarate levels, dynamics, and oxidation state, the α-ketoglutarate dehydrogenase is also
essential in modulating the epigenetic landscape of cancer cells. In this review, we will discuss the manifold
roles that this TCA enzyme and its substrate play in cancer.
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Background
Cancer cells must acquire several biological properties
in order to survive, proliferate, and disseminate. These
functional features, or “hallmarks of cancer”, comprise
sustaining proliferative signaling, evading growth sup-
pressors, escaping cell death, and activating invasion/
metastasis, all of which conspire to lead to pathologically
high levels of cell survival and growth, and ultimately
tumorigenesis [1]. In the last 10 years, an increasing
number of studies suggests that cancer cells reprogram
their metabolism in order to most effectively support
growth and proliferation. Thus, metabolic rewiring has
become an additional hallmark of cancer [1]. Increased
aerobic glycolysis, as initially described by Otto Warburg
[2], is observed in the majority of neoplasms in vivo,
where it is believed to confer advantages to cancer cells
for the production of energy, biomass, and reducing
equivalents [3]. Although Warburg hypothesized that
such a biochemical phenotype arises from the accumula-
tion of mitochondrial defects, it is now known that,
upon nutrient deprivation, oxidative metabolism can
be promptly re-established, and a significant level of
OXPHOS is maintained both in vitro and in vivo [4–9].
A common feature of solid tumors is that cells rapidly
accumulate in bulks, with limited blood supply, and will
hence cope with fluctuations in oxygen and nutrients,
which will inevitably force them to modulate mitochon-
drial function consequently. Interestingly, it has been
shown that neither hypoxia nor OXPHOS defects imply
a complete shutoff of mitochondrial metabolism, and in
either case the tricarboxylic acid (TCA) cycle may ad-
just metabolic fluxes to promote a glutamine-
dependent biosynthetic pathway that sustains tumor
progression [10]. Hence, the TCA cycle represents a
metabolic hub that drives substrate utilization upon
changes in resources availability. With respect to this,
the discovery of mutations in genes encoding key
enzymes of the TCA cycle has brought into light the
importance of intracellular TCA cycle metabolite levels
in modifying both the metabolic and the epigenetic
landscape of cancer cells. Modification of TCA meta-
bolic fluxes and metabolites levels in response to envir-
onmental pressures might therefore account for tumor
adaptation and plasticity in the changing environment.
In this frame, the α-ketoglutarate dehydrogenase complex
(α-KGDC) stands out as being deeply interconnected
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with the respiratory chain, tightly regulated upon tumor
microenvironmental changes, a modulator of the level
of the signaling metabolite α-ketoglutarate (α-KG), a
regulator of cellular redox state, and at the crossroads
of numerous metabolic routes. In this review, we will
discuss the manifold roles this enzymatic complex and
its substrate α-KG play in cancer.
Main text
The α-KGDC in cell metabolism
The TCA cycle is fueled by substrates entering at different
gateways to convey the carbon source for both energy
production and biosynthesis. In the canonical view, acetyl
CoA is provided by the oxidation of carbohydrates, mostly
glucose and fatty acids, and is then condensed with oxalo-
acetate to form citrate. The subsequent series of oxidative
reactions leads to the production of the reducing equiva-
lents NADH and FADH2 that feed respiratory complex I
(CI) and respiratory complex II (CII), respectively, to
generate the mitochondrial membrane potential (Δψm)
required for ATP production. Glutamine, the most
abundant amino acid in the plasma, has been widely
described as an additional key source of both carbon
and nitrogen, especially for fast proliferating cells [11].
Glutaminolysis results in the production of α-KG, either
following dehydrogenation of glutamate or through a
transamination reaction. In turn, α-KG can fuel both
energetic and anabolic pathways: it may be oxidized by
the α-KGDC inside the mitochondria or it may be re-
duced, thereby pushing the TCA cycle towards citrate
[10, 12–14]. The latter may be extruded to the cytosol,
where it may be converted back into acetyl CoA, and
thereby used for lipid biosynthesis.
Hence, the manifold mitochondrial functions allow cells
to rely on different sources of nutrients for energetic and
anabolic purposes. How cells balance the utilization of
these nutrients depends on key metabolic enzymes, whose
activities are modulated in response to genetics and envir-
onmental pressures. In this light, the α-KGDC lies at the
very hub of metabolic pathways and its activity is finely
regulated by the levels of ATP, ADP, inorganic phosphate
(Pi), and by the NADH/NAD+ ratio, which are tightly
dependent on the respiratory chain activity and on the rate
of the glycolytic flux. The product of the α-KGDC reac-
tion, succinyl CoA (Succ-CoA), has been shown to exert a
direct control on the enzyme activity along with calcium
(Ca2+) and reactive oxygen species (ROS) (Fig. 1). Further,
variations of mitochondrial pH and oxygen levels also
Fig. 1 Regulation mechanisms of α-KGDC. α-KGDC is a complex consisting of multiple copies of three enzymes: α-ketoglutarate dehydrogenase
(E1), dihydrolipoamide succinyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). α-KG reacts with the TPP that binds E1, and is thereby
a decarboxylated-generating hydroxyethyl compound. E1 also catalyzes the transfer of two electrons and the acetyl group of the TPP on lipoic
acid (LA), which is bound to the E2 subunit. The reaction performed by E2 is a transesterification in which the thiol group of the Coenzyme A
(CoA) replaces the thiol group of E2, producing Succ-CoA and the reduced form of the lipoic group, the dihydrolipoic acid (DHLA). The sub-
unit E3 catalyzes the transfer of two atoms of hydrogens from DHLA to its prosthetic group FAD, restoring oxidized LA. The reduced FADH2
of the E3 enzyme transfer H+ to NAD+ to form NADH.
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appear to be involved in the regulation of the enzyme.
Hence, the multifactorial modulation of α-KGDC function
may reflect its key role in orchestrating the responses to
the ever-changing metabolic requirements of a cancer cell.
How the α-KGDC contributes to adapt mitochondrial
metabolism to bioenergetic requirements
Structure and energetic regulation of the α-KGDC
In the TCA cycle, the α-KGDC catalyzes the reaction
between α-KG and CoA, using thiamine pyrophosphate
(TPP) as a cofactor and reducing the pyridine nucleotide
NAD+ to NADH, finally generating succ-CoA and CO2.
The α-KGDC is a multienzyme complex composed of
three subunits (Fig. 1). The E1 subunit, encoded by the
human OGDH gene, is a dehydrogenase that catalyzes
the decarboxylation of α-KG, the first step required to
produce succ-CoA. The second step is the reductive suc-
cinylation of the dihydrolipoyl groups, a reaction carried
out by the E2 subunit, i.e., the dihydrolipoamide succi-
nyltransferase, encoded by the human DLST gene. The
E3 subunit, encoded by the human DLD gene, is the
dihydrolipoamide dehydrogenase, which catalyzes the re-
oxidation of the E2 dihydrolipoyl groups, eventually re-
ducing the final acceptor NAD+ to NADH [15]. The
regulation of the α-KGDC highlights a dynamic interplay
between the enzyme and the OXPHOS to adjust mito-
chondrial metabolism through cell energy status sensing.
Both the E1 and the E3 subunits are inhibited by NADH
[16], which accumulates following a decrease of CI func-
tion [17]. Indeed, the latter complex is the first and the
largest of the respiratory chain and catalyzes NADH oxi-
dation to transfer electrons to flavin mononucleotide,
which are used to reduce coenzyme Q to ubiquinol
(QH2). The latter is subsequently used by complex III to
reduce cytochrome c in the mitochondrial intermem-
brane space (IMS), and complex IV uses cytochrome c
to reduce molecular oxygen, which is the final electron
acceptor [18]. Hence, CI actively participates to the gen-
eration of the electrochemical gradient by feeding the
ETC to generate ATP, which makes NADH an essential
substrate for oxidative metabolism. Interestingly, evi-
dence is given for the existence of a direct interaction
between CI and α-KGDC, which not only would provide
an effective NADH oxidation mechanism via substrate
channeling compared to free diffusion [19–21] but also
implicates a higher sensitivity of α-KGDC to NADH
levels, placing the enzyme on the front line to adapt to
variations in ETC efficiency. In addition, a high ADP/
ATP ratio and a high concentration of Pi independently
enhance the activity of the α-KGDC, with a low ADP/
ATP ratio having opposite effects [22, 23]. The levels of
Pi and ADP are indicators of a low energetic condition,
and both molecules act as positive effectors by increas-
ing the affinity of the enzyme for its substrate.
Conversely, higher ATP levels increase the amount of
substrate necessary to reach the half-maximum rate of
the enzyme, therefore reducing its activity [22, 24]. The
regulation of α-KGDC by both the adenine nucleotide
phosphorylation state and the NADH/NAD+ ratio is
tightly dependent on the Δψm: on the one side, ATP ex-
trusion from the mitochondria to the cytosol is con-
trolled by the ADP/ATP carrier that is regulated by high
Δψm and exchanges ATP with ADP in a 1:1 ratio [25].
On the other side, in cases when the ETC is damaged,
the production of mitochondrial NADH, driven by cyto-
solic reductive power, is decreased [26]. This implies that
the energetic control on the α-KGDC might be exclu-
sively mitochondrial, and that a feedback loop relying on
both substrate and energy availability is triggered be-
tween the OXPHOS and the enzyme, thereby ensuring
an optimal cooperation. In this light, it may be envi-
sioned that a decrease in mitochondrial respiration, or a
significant ATP accumulation, may be associated with a
decrease in α-KGDC activity. Changes in the enzyme
function would in turn balance mitochondrial NADH
levels, thus modulating CI activity and thereby ATP pro-
duction. However, it has been observed in human neuro-
blastoma cells that decreasing α-KGDC activity up to half
its maximum decreases neither Δψm nor mitochondrial
ATP levels [27]. In line with this, the existence of a thresh-
old for the α-KGDC capacity has been demonstrated,
which can be greatly inhibited before affecting the max-
imal mitochondrial oxygen consumption rate [28]. NADH
levels can therefore vary broadly before becoming a limit-
ing factor for cellular respiration, suggesting that any re-
duction of α-KGDC activity might represent a first
attempt to adapt metabolism by modulating TCA flux, be-
fore impinging on ETC function.
Calcium-mediated regulation of the α-KGDC
The relationship between α-KGDC and Ca2+ further em-
phasizes the pivotal role of the enzyme in regulating cell
metabolism. The mitochondria have long been thought
to be a Ca2+ sink, with the main scope of regulating this
cation homeostasis in cells. Cytosolic Ca2+ has been
shown to foster NADH oxidation by the glycerol de-
hydrogenase to ultimately produce and import FADH2
within the mitochondria as a substrate for CII [29]. Fur-
thermore, Ca2+ stimulates NADH production through
the reactions of the TCA enzymes pyruvate dehydrogen-
ase (PDH), isocitrate dehydrogenase (IDH) and α-KGDC
[16, 30]. Among these three enzymes, α-KGDC has been
shown to be the most responsive to Ca2+, as the cation
lowers the enzyme KM for α-KG [22, 25, 29, 31]. Interest-
ingly, the sensibility of α-KGDC to Ca2+ depends on the
concentration of NADH, and on the ATP/ADP ratio, again
highlighting a regulatory role of the ETC on the enzyme ac-
tivity. Indeed, an increase in both cofactors lowers α-KGDC
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stimulation by Ca2+ [24]. Also, calcium enters the mito-
chondria through a uniporter, a process driven by the nega-
tive potential across the IMM [32]. With respect to this,
cancer cells have been shown to be particularly sensitive to
an arrest of mitochondrial metabolism through the inhib-
ition of Ca2+ transfer into the mitochondria. Indeed, while
normal cells slow down proliferation when Ca2+ import is
inhibited, cancer cells proceed through mitosis and end up
necrotic, a route that may be rescued through dimethyl-α-
KG supplementation [33]. This finding indicates that cancer
cells ought to rely on a functional TCA cycle to sustain suc-
cessful proliferation, and that α-KG may help overcome cal-
cium shortage and sustain a minimal OXPHOS activity, or
may drive adaptive responses to oxidative metabolism
impairment.
pH-mediated regulation of the α-KGDC
A tight link between α-KGDC and OXPHOS is further
exemplified when considering the role of pH in α-KGDC
regulation. It has been widely shown that cytosolic Ca2+
elevation leads to rapid mitochondrial acidification,
boosting oxidative metabolism. A range of pH between
6.6 and 7.4 has been demonstrated to increase α-KGDC
activity [22]. Nonetheless, cytosolic pH is ~7.6 whereas
in the mitochondrial matrix it ranges between 7.5 and
8.2 [34, 35]. The α-KGDC activity would thus be pro-
moted upon environment acidification. In agreement
with this, α-KG concentration in acidotic rat kidneys
significantly decreases due to an increase of α-KGDC ac-
tivity [36], which raises the question of whether changes
in pH affect mitochondrial function in cancers, since
they mostly rely on aerobic glycolysis and undergo a
prominent acidosis [2]. However, cancer cells secrete
lactate/H+ to maintain intracellular pH at physiological
values, leading to the acidification of the extracellular
microenvironment [37]. Noticeably, pH in the mito-
chondria is inherently related to the activity of the ETC
that is driven by the proton motive force and Δψm [18].
Thus, the pH of the mitochondrial matrix would rather
reflect the equilibrium between proton extrusion and
entry into the matrix, mainly driven by OXPHOS activ-
ity [38]. It may be easily argued that a low OXPHOS
activity is associated with a decrease of pH in the mito-
chondrial matrix due to proton accumulation, at least
around the inner membrane. In this respect, the subse-
quent induction of α-KGDC activity and of the subse-
quent NADH generation might help maintaining a
proper chemical gradient by fostering CI proton pump-
ing in the IMS. Hence, beside the adenine nucleotide
phosphorylation state, the NADH/NAD+ ratio and cal-
cium levels, the OXPHOS might exert an additional
control on the α-KGDC through the modulation of pH
in the matrix of mitochondria.
ROS and α-KGDC activity
ROS are by-products of mitochondrial oxidative metab-
olism and their levels are a reliable indicator of ETC
damage [39]. Noteworthy, α-KGDC can both sense and
generate ROS (Fig. 1). An increase in ROS levels may
decrease or completely inhibit α-KGDC function via two
different mechanisms involving the modification of LA.
While a post-translational modification may lead to the
partial and reversible inhibition of the enzyme, the gener-
ation of a thiyl radical on the cofactor precedes its
complete inactivation [40–42]. On the other hand, in re-
sponse to NADH accumulation, stimulated by increased
α-KG levels, the E3 subunit may generate H2O2 [43, 44]
(Fig. 1) at much higher levels than CI [45]. Although
physiological amounts of ROS are essential for cell sur-
vival, their excess fosters cancer initiation and progression
through the induction of genomic instability, gene expres-
sion modifications, and the activation of signaling path-
ways [46, 47]. The aconitase is the most ROS-sensitive
TCA cycle enzyme [48], and its inhibition in cells may
therefore limit NADH production by interrupting the
cycle from pyruvate to α-KG, and thus electron flux
through the respiratory chain, ultimately reducing ROS
in a negative loop. Conversely, cancer cells’ high reliance
on glutamine metabolism may allow the α-KGDC to
fully sustain NADH-linked respiration [49], even upon a
great reduction of aconitase activity. However, unlike the
latter, high ROS levels are required to inhibit the α-KGDC
[42]. In this light, the elevated threshold might play a
prominent role in the progression of tumors with ETC de-
fects. Similarly, prolonged metabolic perturbations such as
NADH and α-KG accumulation may lead to α-KGDC-
dependent oxidative stress, which in turn may profoundly
affect cancer cell redox state and metabolism through a
ROS-mediated self-inactivation of the enzyme [50]. Based
on these characteristics, with the aim of proposing poten-
tial anti-cancer treatment, Stuart and co-workers de-
scribed a member of anti-cancer lipoate derivatives, CPI-
613, which induces an E3-mediated burst of ROS leading
to E2 inactivation in cancer cells [51]. Although CPI-613
is known to be implicated in cell death, whether this is
due to α-KGDC inhibition, ROS overproduction, or to the
reduction of the activity of other lipoate-dependent mito-
chondrial metabolic enzymes remains unclear [51, 52].
The α-KGDC in cancer metabolic reprogramming
Glucose and glutamine are the two primary nutrients
utilized by cancer cells [11]. However, unlike glucose,
which only provides carbon for biosynthesis, glutamine
can provide both carbon and nitrogen for anabolic reac-
tions, thereby conferring substantial additional benefits
[53]. Cancer cells also depend on lipid biosynthesis for
biomass increase [54–56]. A crucial precursor of fatty
acids biosynthesis is the citrate that is canonically
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provided by glucose and glutamine metabolism through
a forward running TCA cycle [10]. Instead, in neoplastic
cells under hypoxic condition or in the presence of ETC
defects, citrate is generated from reductive carboxylation
of glutamine-derived α-KG, by cytosolic and mitochondrial
NADPH-dependent IDH1 and 2, respectively [12, 13]. The
α-KG conversion to isocitrate implies a lower α-KGDC ac-
tivity and the unbalance of the α-KG/citrate ratio, leading
to a TCA cycle functioning in a reverse mode, ultimately
supporting de novo fatty acids synthesis and favoring
tumor growth [13, 56, 57] (Fig. 2). It is worth noting that
the activity of the α-KGDC is reduced via the hypoxia
inducible factor 1 (HIF1)-mediated degradation of a splice
variant of the E1 subunit, whose prevention renders cancer
cells dependent on citrate or exogenous lipids to prolifer-
ate, and impedes tumor growth in vivo [56]. HIF1, the
master regulator of the hypoxic response in malignant can-
cer cells [58], might also contribute to increase the α-KG/
citrate ratio by inhibiting the activity of PDH and therefore
citrate generation [59, 60] (Fig. 2a). These findings high-
light an important role for HIF1 in modulating TCA
metabolites levels and in the rewiring of α-KG fate from
oxidative to reductive metabolism. In line with this, it has
been shown that, in normoxia, constitutive activation of
HIF1 alone is able to promote the reductive carboxylation
of α-KG [12, 57]. Nevertheless, HIF1 is not essential in
Fig. 2 Scheme of the molecular actors driving α-KG reductive carboxylation in mitochondria upon hypoxia (a) and in cancer cells with ETC de-
fects (b). Reductive carboxylation requires the elevation of the α-KG/citrate ratio and reduces α-KG to isocitrate that is subsequently converted to
citrate. This latter is shuttled to the cytosol where it is used for the biosynthesis of lipids. Noteworthy, in both cases (a-b), ROS production by ETC
and α-KGDC may induce the inhibition of aconitase and α-KGDC, thereby preventing citrate and α-KG oxidation, respectively. a Upon hypoxia
(5–0.5% O2 tension), HIF1 can participate to the increase of the α-KG/citrate ratio, by preventing both PDH and α-KGDC activity, in turn limit-
ing citrate production and α-KG oxidation, respectively. (b) In cancer cells with ETC defects, the accumulation of NADH may lead to the inhib-
ition of mitochondrial NADH-dehydrogenases (PDH, IDH, and α-KGDC), thus decreasing citrate production/oxidation and α-KG oxidation.
Further, NADH increase may also promote NADPH-dependent IDH1/2 activity. Finally, it is important to note that NADH accumulation might
also foster reductive carboxylation under low oxygen tension. The TCA metabolic flux is represented by blue arrows ( ), and ( ) indicate
the specific enzyme for each TCA cycle step. Ac-CoA (Acetyl-Coenzyme A; Aco (aconitase); Cit (citrate); Isocit (Isocitrate); Gln (Glutamine);
α-KG (α-ketoglutarate)
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driving the reduction of α-KG since any conditions
leading to a high α-KG to citrate ratio might promote
it, by mass action on the TCA cycle flux [14]. For in-
stance, in hypoxia and in cancer cells with ETC defects,
the decrease of α-KG oxidation may be driven by
changes in the levels of reducing equivalents. In this
scenario, modifications of the mitochondrial redox state
might account for the inhibition of the TCA dehydroge-
nases α-KGDC and PDH and for the promotion of the
NADPH-dependent IDHs [12, 14, 61, 62] (Fig. 2b). Fur-
thermore, ETC defects or hypoxia often lead to increase
in ROS [63], which may contribute to the reduction of
α-KGDC and aconitase activity. In this condition, the
ROS-mediated inhibition of α-KGDC might foster α-KG
accumulation and its diversion towards lipid biosyn-
thesis, while the inactivation of aconitase might con-
tribute to the accumulation and the extrusion of citrate
from mitochondria [64] (Fig. 2).
Silencing OGDH in cancer cells with mitochondrial
defects has been shown to prevent the production of
sufficient levels of NADH, ultimately increasing the
NADP+/NADPH ratio and preventing the NADPH-
dependent IDHs to reduce α-KG [13]. This observation
demonstrates that a minimal activity of α-KGDC is es-
sential for the occurrence of reductive carboxylation and
that this enzyme may operate even in the presence of
respiration defects. Accordingly, HIF1 does not mediate
a complete inhibition of α-KGDC activity, but only up
to approximately 60% [56]. Moreover, accumulation of
α-KG represses HIF1α stabilization and its downstream
pathway by fostering the activity of the metabolic sensor
prolyl hydroxylases (PHDs). This may represent a feed-
back control to keep the enzyme under the stringent
regulation required for metabolic adaptation to hypoxia.
To the same extent, the NADH and ROS-mediated
regulation of α-KGDC activity represents additional
feedback mechanisms that prevent complete enzyme
inactivation. Since the forward and reverse modes of the
TCA cycle are not exclusive, a fine-tuning of α-KGDC
activity is required to balance α-KG fate in both ener-
getic and anabolic pathways, according to oxygen levels
and to ETC status.
In great contrast with impaired respiration, conditions
of nutrient deprivation lead to OXPHOS enhancement
and increase the NAD+/NADH ratio in the matrix,
hence promoting mitochondrial biogenesis, fatty acids
oxidation, and preventing oxidative stress [65, 66]. Sur-
prisingly, a decrease in α-KGDC activity and thereby of
mitochondrial ATP synthesis, due to the accumulation
of α-KG and subsequent inhibition of the ATP synthase,
has been shown to mimic calorie restriction in Caenor-
habditis elegans [67]. This mechanism is proposed to
ensure energetic efficiency in response to nutrient
deprivation [67] and suggests that decreasing α-KGDC
activity is not in contradiction with optimal cellular res-
piration. However, the accumulation of α-KG in starved
animals appears to come from an increase in glutamine
metabolism to sustain anaplerotic gluconeogenesis
from amino acids catabolism and not from a decrease
in α-KGDC activity [68]. Thus, the relevance of this
mechanism has yet to be proven in cancer cells, where
nutrient requirements and metabolic networks are
known to be drastically different from non-malignant
cells. In cancer cells, glutaminolysis exceeds the cellular
requirement for glutamine in the production of amino
acids, nucleotides, and energy [69]. Duràn and co-workers
have shown that α-KG levels are a crucial sign of amino
acids availability status. In this scenario, high cytosolic
levels of α-KG may promote mammalian target of rapa-
mycin 1 (mTORC1) signaling, which in turn blocks au-
tophagy, the housekeeping mechanism to survive nutrient
deprivation stress, and increases anabolism in neoplastic
cells. On the other hand, low levels of α-KG have opposite
effects and correlate with reduced mitochondrial respir-
ation and ATP levels [70, 71]. In this light, it might be
hypothesized that the high α-KG production due to
enhanced glutamine metabolism might be beneficial for
cancer cells by promoting proliferation while inhibiting
autophagy [72]. However, the complex interplay between
glutamine metabolism and the regulation of mTOR and
autophagic processes in cancer cells makes an uncertainty
whether α-KG plays a pivotal role in this respect [73]. In
addition, upon glucose deprivation, treatment with α-KG
derivatives and its reduced form 2-hydroxyglutarate (2-
HG) has revealed the ability to inhibit the ATP synthase,
resulting in mTOR signaling reduction and autophagy
blockage in cancer cells [74]. Overall, these findings
suggest that α-KG levels variation may differently affect
autophagy regulation according to nutrient availability
and compartmentalization of the metabolite (i.e., cyto-
solic versus mitochondrial), whose regulation still war-
rants investigation.
Is α-KG an oncometabolite?
Mutations in fumarate hydratase (FH), succinate de-
hydrogenase (SDH), and IDH1 and IDH2 are associated
to specific human neoplasms that hence accumulate suc-
cinate, fumarate, and (R)-2-HG, respectively, all convey-
ing broad oncogenic signals [75]. Mutations in FH and
SDH follow the classic Knudson “two-hit” model, with
somatic loss of gene function leading to the accumula-
tion of their substrates. In a non-canonic fashion, a sin-
gle allele mutation in IDH1/2 creates a neomorphic
enzyme with increased affinity for α-KG, from which an
excess of the (R)-2-HG metabolite is produced [75, 76].
The prime mechanism of action of these so-called
“oncometabolites” lies within the fact that they are struc-
turally and metabolically similar to α-KG and retain the
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capacity to regulate a family of more than 60 enzymes
involved in fatty acid metabolism, collagen biosynthesis,
nutrient sensing, oxygen sensing, and epigenome editing
[77, 78]. These enzymes are the Fe(II)/α-KG-dependent
dioxygenases, and they include the PHDs introduced
earlier. They are ubiquitously expressed and catalyze hy-
droxylation reactions on several targets. Moreover, they
all use α-KG and O2 as co-substrates and require Fe(II)
as a cofactor to produce succinate and CO2 [79]. Add-
itionally, ascorbate is required to induce the reduction of
Fe(III) to Fe(II), thus restoring enzyme activity [80, 81].
Noticeably, even in the absence of O2, α-KG alone is
sufficient to promote the activity of a subset of Fe(II)/
α-KG-dependent dioxygenases, [82], which are instead
inhibited by succinate and fumarate [83]. (R)-2-HG oc-
cupies the same binding site of α-KG and thereby acts
as a competitive inhibitor [84]. Since the KM of dioxy-
genases for α-KG is close to the metabolite physio-
logical concentration, any condition causing even a
modest variation in the cytosolic levels of α-KG may
profoundly modify dioxygenases-mediated signals.
Understanding α-KG dynamics and their effect on its
downstream targets
A comprehensive identification of enzymes that use α-
KG to carry out their reactions will help to better define
the metabolite role in bridging mitochondrial function
to metabolic reprogramming in cancer cells. In this
frame, PHDs have been extensively studied, in particular
for their role in the response to hypoxia by determining
HIF1α stabilization (Fig. 3). The transcription factor
HIF1 consists of an α- and a β-subunit, which are both
constitutively produced. Under normoxic conditions,
HIF1α is degraded following the hydroxylation of two
specific prolyl residues in its oxygen-dependent degrad-
ation domain (ODDD), operated by three different en-
zymes, namely PDH1, 2, and 3. This in turn recruits an
E3 ubiquitin ligase complex containing the Von Hippel
Lindau protein (pVHL), resulting in HIF1α ubiquityla-
tion and subsequent degradation by the proteasome.
Conversely, in hypoxia, the PHDs low affinity for oxygen
does not allow them to hydroxylate HIF1α, which can-
not be degraded and becomes stabilized. Although the
three PHDs have been reported to be competitively
inhibited by several TCA metabolites and pyruvate
[83, 85–88], the most consistent effects are observed
with fumarate and succinate [88] (Fig. 3). Accordingly,
chronic inhibition of PHDs in both SDH-deficient and
FH-deficient tumors is associated with the stabilization
of HIF1α and activation of downstream hypoxic path-
ways even in normoxia (i.e., pseudohypoxia) [87]. Never-
theless, it is yet unclear whether the pseudohypoxic
response caused by TCA cycle defects is sufficient per se
to promote tumorigenesis or to support tumor progres-
sion [75]. Accumulation of α-KG, on the other hand,
may have an opposite effect and rather lead to the con-
stitutive destabilization of HIF1α. Accordingly, Gottlieb
and his group have shown that the increase in α-KG
alone is sufficient to oppose succinate, fumarate, and
hypoxia-mediated activation of HIF1α. This resulted
in the reversal of enhanced glycolysis and cell death
[82, 89]. Hence, the levels of α-KG, even in hypoxia,
may be sufficient to foster PHD activity and prevent
the hypoxic response. In line with this, our group has
Fig. 3 Schematic representation of the influence of α-KG levels and compartmentalization on PHDs and ATP synthase. PHDs have a dual role in
the context of cell response to resources availability. PHDs control both adaptations to reduced oxygen levels, through HIF1α destabilization, and
to nutrient availability via mTOR promotion. Cytosolic accumulation of α-KG may promote both PHDs and mTOR pathway and may inhibit HIF1
signaling. Conversely, mitochondrial accumulation of α-KG may prevent mTOR activation through the ATP synthase inhibition
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demonstrated that cancer cells with severe mitochon-
drial CI impairment display an increase of α-KG/succin-
ate ratio, likely due to an inhibition of α-KGDC resulting
from an increased NADH/NAD+ ratio. This accumula-
tion is associated to a constitutive destabilization of
HIF1α even in a hypoxic environment (i.e., pseudonor-
moxia), together with a reduction of the tumorigenic
potential in vivo [62, 90–92]. Importantly, both mito-
chondrial impairment and hypoxia can lead to the over-
production of L-(R)-2-HG, which is mostly generated
by the conversion of glutamine-derived α-KG and com-
petes with the latter [12, 61, 93–95]. Thus, dioxy-
genases would respond to the (L)-2-HG/α-KG ratio
rather than to α-KG levels. Unlike (R)-2-HG, the L en-
antiomer does not stem from IDH1 or IDH2 mutations,
but via a promiscuous activity of lactate dehydrogenase
A (LDHA), MDH1 and PHGDH in the cytosol, and via
MDH2 activity in the mitochondria, in a NADH-
dependent manner [93, 96–98]. Hence, changes in the
redox state as NADH accumulation and the subsequent
modification of enzymatic functions associated to im-
paired respiration would foster α-KG conversion into
(L)-2-HG. It has recently been remarked that an essen-
tial role of the respiratory chain is to transfer electrons
from reduced substrate to oxygen, thereby maintaining
an adequate redox state to allow aspartate synthesis
and sustain cancer proliferation [26, 99]. In this con-
text, it is plausible to envision that the α-KG may alter-
natively accept electrons and become reduced to (L)-2-
HG, behaving as a de facto substitute of the ETC to
support cancer growth. Consistently with this, supple-
mentation with α-KG or inhibition of α-KGDC in nor-
moxia causes a slight increase in (L)-2-HG levels,
whereas in hypoxia the increase is far higher [93]. In the
presence of respiration defects, on the other hand, the
subsequent accumulation of α-KG might have different
effects depending on its conversion rate into (L)-2-HG,
as the enantiomer may inactivate PHDs over a certain
threshold. It appears unlikely that the reduction of
OXPHOS alone is sufficient to drive the (L)-2-HG-medi-
ated HIF1 response, since, as shown by our group, a se-
vere CI impairment rather prevents HIF1α stabilization.
Additional factors would thus be required (Fig. 4).
Besides low PHD activity due to the oxygen shortage,
additional mechanisms may be envisioned. For instance,
in physiological situations, the (L)-2-HG dehydrogenase
(L2HGDH) converts (L)-2-HG back to α-KG [100],
whereas in hypoxia L2HGDH expression is decreased by
50% and is therefore important to maintain a high (L)-2-
HG/α-KG ratio (Fig. 4). Furthermore, a low L2HGDH
activity would promote the production of ROS [93] with
consequent HIF1α stabilization [101] (Fig. 4). It is re-
markable that the regulation of L2HGDH expression is
HIF1-independent, thus suggesting a potential upstream
role in the initiation of the hypoxic response. Strikingly
however, a recent study carried out by Burr and co-
workers has shown that disruption of OGDH leads to
HIF1α accumulation in normoxia via a ROS-independent
PHD2-mediated mechanism that relies on (L)-2-HG pro-
duction through both MDH1/2 and LDHA [102]. Hence,
while cell response to hypoxia is mediated by multiple sig-
nals, including O2, reductive equivalents, α-KG, (L)-2-HG
and ROS, the modulation of α-KGDC activity alone may
have a great impact on HIF1α stabilization. To support
this, it was shown that decreasing PHD activity does not
inevitably promote the HIF1-signaling pathway, even in
hypoxia. This seems to depend on a diminished HIF1α
translation, due to a decreased mTOR signaling that
follows O2 and amino acids deprivation, and hence, low
levels of cytosolic α-KG, as PHDs are enhancers of mTOR
activity (Fig. 3) [71]. Both low and high levels of α-KG
may therefore impede the hypoxic response, suggesting
that the maintenance of a certain α-KG amount is essen-
tial for HIF1 activation. In this light, it is possible to
speculate that maintaining α-KGDC activity in an appro-
priate range would not only permit cells to meet meta-
bolic requirements in hypoxia but it would also accurately
control α-KG and (L)-2-HG levels in order to provide cells
with a tailored signal for HIF1 activation.
Besides mTOR, autophagy is also modulated by HIF1
[103], making PHDs and thereby α-KG levels pivotal in
organelles catabolism. Accumulation of α-KG may also
promote mTOR function via ATP synthase inhibition in
the mitochondrion, without involving PHDs [67] (Fig. 3).
Hence, while cytosolic accumulation of α-KG might
prevent autophagy by activating PHDs, the elevation of
its levels in the mitochondria would instead promote it,
via ATP synthase inhibition. Nonetheless, cytosolic
Fe(II)/α-KG-dependent dioxygenases respond to the
ratio between α-KG and its various competitors, whereas
α-KG mediates the inhibition of ATP synthase in a non-
competitive manner [67]. Consequently, the former
mechanism is sensitive to high cytosolic α-KG/2-HG
ratio, generated by an increase in amino acids metabol-
ism or a decrease in OXPHOS. The latter may instead
be triggered by both α-KG and its reduced forms in the
mitochondrial matrix with respect to ATP synthase
abundance, and would serve to optimize cell respiration
according to substrate availability, thereby contributing
to caloric restriction adaptation.
In conclusion, the response to fluctuations of α-KG
levels in cells is multifactorial and remains an open area
of research. The α-KG signaling is likely to be defined by
the metabolite abundance, its oxidation state, and dy-
namics, which are determined by ETC status and oxygen
levels, perhaps among other yet unknown mechanisms.
Based on these considerations, it is plausible to argue
that fluctuations of α-KG levels may be an intrinsic
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characteristic of tumor progression, useful to trigger the
bioenergetic changes in response to selective pressures.
In this light, the role of α-KG remains dual as it may
promote both oncogenic and tumor suppressive func-
tions, paralleling the oncojanus function of mitochon-
drial genes, as we have previously proposed [91].
Impact of α-ketoglutarate on cancer cell epigenetics
Epigenetics alterations at both DNA and histone levels
are increasingly being recognized as modifiers of tumori-
genesis [104]. CpG islands are widely hypermethylated
in many cancer types compared to the corresponding
normal tissue, while the rest of the genome is rather
subject to demethylation. The hypermethylation of CpG
islands has been utilized as a criterion to distinguish dif-
ferent tumor types from non-malignant tissue [105], and
tumors characterized by high levels of DNA methylation
have been classified as having a CpG island methylator
phenotype and are predominantly associated with worse
prognosis, potentially due to a silencing of tumor sup-
pressor genes. In many cases, this phenotype originates
in early phases of tumorigenesis of many tumor types
such as glioblastomas, acute myeloid leukemias, gastric
cancer, and ependymomas [106–111], where drugs tar-
geting the DNA methylation machinery are a promising
strategy.
The large family of α-KG-dependent dioxygenases in-
cludes two classes of enzymes involved in demethylation
and hydroxylation reactions of DNA and histones. The
ten-eleven translocation hydroxylases (TET 1 to 3)
catalyze DNA demethylation, whereas the Jumonji C
domain containing lysine demethylases (KDM 2 to 7) is
the largest family of histone demethylases [112–114].
Both (L)-2-HG and (R)-2-HG are competitive inhibitors of
TETs and KDMs, and are thus important modifiers of the
epigenetic landscape of cancer cells [84, 94, 115, 116]. Ac-
cordingly, accumulation of (L)-2-HG and (R)-2-HG has
been associated to several types of cancers [96, 117–119].
Similarly, recent studies have revealed that together with
2HGs, succinate and fumarate can also induce alterations
in DNA and histones methylation, thus enhancing cancer
formation [84, 120–125]. These findings suggest that
Fig. 4 Mitochondrial signals that shape the HIF1-mediated metabolic and hypoxic adaptation in cancer cells. The hypoxic response may originate both
from HIF1α stabilization, via the decrease in oxygen levels and the increase in the (L)-2-HG/α-KG ratio that lower PHDs activity, and from HIF1 activation,
due to high ROS levels. In the first instance, reduced oxygen levels may inhibit the L2HGDH activity thereby decreasing (L)-2-HG conversion into α-KG,
together with fostering ROS production. Additionally, the elevation of NADH levels in the mitochondria that stems from decreased respiration inhibits
the malate-aspartate shuttle (MAS) and therefore mitochondrial NADH production from cytosolic reductive power. Both mitochondrial and cytosolic
NADH accumulation foster the activity of the NADH-dependent enzymes MDH1/2, PHGDH and LDHA that convert α-KG into (L)-2-HG.
Furthermore, the potential production of ROS by the ETC and α-KGDC might further promote HIF1 activation. Finally, both NADH and HIF1
may inhibit α-KGDC and PDH, further promoting α-KG accumulation, in turn converted into (L)-2-HG or utilized for lipid biosynthesis
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different cytosolic concentrations of α-KG affect the
methylation status of both histones and DNA and thereby
trigger epigenetic changes. Accordingly, Thompson’s
group has demonstrated how maintenance of a proper
α-KG to succinate ratio is fundamental to determine
the identity and the fate of embryonic stem cells (ESC)
[126]. In particular, a high α-KG/succinate ratio pro-
motes the activity of DNA and histone demethylases,
and modifying this ratio is sufficient to regulate multiple
chromatin modifications. Indeed, treatment with α-KG
supports ESC self-renewal, which is known to display
an unusual “open” chromatin structure, associated to
hypertranscription [127]. In this light, high cytosolic
levels of α-KG would promote high energy-consuming
processes, a hypothesis that is supported by the exist-
ence of the PHD-driven mTOR activation mediated by
α-KG, which fosters anabolic processes. Conversely, in
cancer cells facing hypoxia, it is plausible that α-KG con-
version into (L)-2-HG most likely helps in reducing the
energetic demand while promoting HIF1α stabilization
for hypoxic adaptation. Consistent with this, hypoxia
induces a global increase in trimethylation of histone H3
at lysine 9 (H3K9me3) marks, known to repress gene
expression, through the accumulation of (L)-2-HG that
inhibits the activity of the demethylase KDM4C [94].
Furthermore, oxygen shortage has recently been shown
to directly cause DNA hypermethylation by reducing
TET activity in cancer cells, predominantly at the level
of gene promoters [128]. Notwithstanding this, both
TETs and KDMs may stimulate the transcription of spe-
cific HIF1-targeted genes, while being themselves tran-
scriptional targets of HIF1 [125, 128–133], a mechanism
that most likely compensates for their lower enzymatic
activity. Hence, while oncometabolites and low oxygen
availability can promote a closed chromatin state and a
drop in global gene expression through α-KG-dependent
dioxygenases activity, it is plausible that retaining a
minimal activity of these enzymes would induce a spe-
cific genetic response in cells by restraining transcrip-
tion machinery to HIF1-targeted genes.
Similarly, given the role of α-KG as an indicator of
amino acids availability, it is plausible to speculate the
occurrence of an epigenetic remodeling upon glutamine
deprivation, which may be faced by solid cancers. Ac-
cordingly, a recent study has demonstrated that glutam-
ine deficiency is associated to low α-KG levels, which may
in turn determine the inhibition of KDMs in the core re-
gions of the tumor. In this context, the increase in histone
methylation induces cancer cells dedifferentiation and
may cause therapy resistance [134].
The consequence of epigenetics modifications is the
transduction of external stimuli into a transcriptional re-
sponse, thus adjusting cells phenotype without affecting
their genotype [135]. It is most likely that cell bioenergetic
changes driven by external and internal selective pressures
promote an intricate epigenetic remodeling through
α-KG signaling.
Conclusions
A revisited role of mitochondria highlights that they are
not mere bystanders during carcinogenesis. The ever-
changing tumor microenvironment may force cells to
rely on fluctuating levels of oxygen, as well as varying
availability and types of nutrients, whereby optimization
of substrates utilization and a continuous restructuring
of both metabolic and genetic signatures becomes
mandatory for survival. In this review, we have
highlighted a hub role for the TCA cycle enzyme α-
KGDC as a front-line player in the adaptation of cancer
cells to a demanding environment in vivo. This enzyme
may be considered a gatekeeper of the OXPHOS system
and one of the major regulators of mitochondrial metab-
olism. Indeed, α-KGDC responds to OXPHOS activity
fluctuations, controls the mitochondrial redox status
through NADH and ROS levels balance, and directs the
TCA metabolite fluxes towards energetic, anabolic, and
signaling pathways. Changes in α-KGDC activity, and con-
sequently in overall mitochondrial bioenergetics, may im-
pact not only on TCA cycle fluxes but may become
amplified and eventually drive an intricate metabolic and
epigenetic remodeling. Overall, NADH/NAD+ and AMP/
ATP ratio, oxidative stress, membrane potential, and oxy-
gen levels are pivotal players in the translation of the α-
KG signal. In turn, α-KG and its reduced forms may influ-
ence the activity of dioxygenases to shape cells metabolic
and epigenetic landscape according to oxygen and nutri-
ent availability and ETC efficiency. In this light, the α-
KGDC and its substrate appear to be inescapable actors
in cancer cells plasticity. It is remarkable that genetic
and metabolic modifications within a tumor mass are
likely to differ from cell to cell thereby contributing to a
phenotypic heterogeneity, thus accounting for therapy
resistance and disease progression [134, 136]. Several
studies have considered the anti-tumorigenic properties
of α-KG but its mechanisms of action are still not fully
understood. The anti-tumorigenic effect observed upon
in vivo treatment with derivatives of α-KG has been
shown not only to depend on impaired HIF1 signaling
pathway but also to a much greater extent on multiple
unknown side effects of α-KG on tumor growth [94]. In
this frame, it has been reported that α-KG antagonizes
the effect of other oncometabolites, and might therefore
be considered a tumor suppressor metabolite. Neverthe-
less, α-KG supplementation leads to the risk of feeding
oncogenic pathways not only due to its conversion into
(L)-2-HG in respiratory deficient cells but also into suc-
cinate and fumarate, on a long-term treatment [137]. On
the other hand, several human Fe(II)/α-KG-dependent
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dioxygenases have been investigated as possible thera-
peutic targets and might represent an interesting alter-
native strategy to render tumors more sensitive to
radiotherapy and chemotherapy [90]. A complete un-
derstanding of the α-KG-mediated interplay between
metabolic and genetic reprogramming will help us to
disclose a new therapeutic window in which cancer
progression can be restrained. While cancer is defined
as a genetic disease, there is nowadays a growing and
legitimate interest in its metabolic dimension. In par-
ticular, these two aspects are increasingly recognized as
being so interconnected that they are likely to represent
the two edges of the same sword.
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